It protects against 15 serotypes. PCV20, also known as Prevnar 20, was licensed in 2021 for adults 18 years and older, then in 2023 was recommended for ages 6 weeks and up. It covers 20 serotypes.

Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults: Rahway, New Jersey Friday, March 28, 2025, 09: ...